Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
By David Carnevali
NEW YORK (Reuters) - AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.
The acquisition would come just days after AbbVie agreed to buy cancer drug developer ImmunoGen Inc for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines.
AbbVie is in talks to pay around $45 per share for Cerevel, which is backed by private equity firm Bain Capital, the sources said.
If the negotiations conclude successfully, a deal could be announced as early as this week, the sources added, requesting anonymity because the matter is confidential.
AbbVie and Cerevel did not immediately respond to requests for comment.
Cerevel shares jumped 14% to $42.20 in afterhours trading in New York on Wednesday.
(Reporting by David Carnevali in New York; Editing by Greg Roumeliotis)
